How can we get to zero unregistered clinical trials? Elizabeth Loder discusses. […]
Editors at large
Tessa Richards: Power to the people—via Paris
Who gets to define value in health systems? The notion that it should be the people who use their services, rather than those who provide them, is gaining momentum. At […]
BMJ in the News 2016: Medical errors, Zika, and Pokémon make global news headlines
Medicine and health regularly dominate news headlines—and this year was no different. The Zika outbreak, NHS crisis, and countless studies on nutrition, diet, and fitness were among those to make […]
News review 2016: Corruption, Polish trainees, Zika, and dementia top the news hit parade in 2016
News items about fraud and corruption in healthcare always attract a lot of attention, and 2016 was no exception. The most popular story on bmj.com this year concerned scientists at […]
Tessa Richards: Patients combat corruption in healthcare
Corruption in health systems has been described as “one of the biggest open sores in medicine.” It occurs in many guises and all countries. Patients may be unaware of the price […]
Joe Freer: Patient advocacy for antimicrobial resistance
“It was a good idea to get an economist to lead the review,” said Lord Jim O’Neill in Westminster yesterday*, referring respectively to himself and his 2016 report on Tackling […]
Tiago Villanueva: Family medicine and private health insurance in Portugal
I read with interest some recent articles about the interplay between private healthcare insurance and state provided healthcare. [1][2][3] A substantial proportion of the population has private health insurance in […]
Helen Macdonald: Fixing evidence based medicine
Love it or hate it—we must all consume evidence. Now is your chance to have your say on what its future should be like. Yesterday the Centre for Evidence Based Medicine at Oxford […]
Tessa Richards: WHO and the politics of health
Gaining cross country consensus on joint European strategies to tackle politically and culturally sensitive public health issues is not easy. So it was not surprising perhaps that a decision to […]
Elizabeth Loder: Should orange be the new black for price-gouging pharma execs?
One thing’s for sure: Heather Bresch, the CEO of Mylan Pharmaceuticals, looks good in orange. She’s the subject of a recent New York Times article that opens by declaring “America has […]